Search

Amphastar Pharmaceuticals Inc

Avatud

SektorTervishoid

19.79 -1.98

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

19.62

Max

20.32

Põhinäitajad

By Trading Economics

Sissetulek

-18M

6.4M

Müük

-12M

171M

P/E

Sektori keskmine

11.554

64.641

Aktsiakasum

0.42

Kasumimarginaal

3.751

Töötajad

1,976

EBITDA

-5.4M

33M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+8.8% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

6. aug 2026

Turustatistika

By TradingEconomics

Turukapital

-167M

846M

Eelmine avamishind

21.77

Eelmine sulgemishind

19.79

Uudiste sentiment

By Acuity

14%

86%

19 / 340 Pingereas Healthcare

Amphastar Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. aug 2026, 19:46 UTC

Amphastar Pharmaceuticals Inc is trading higher, reaching a session high amid positive market conditions and falling oil prices influencing investor sentiment.

31. juuli 2026, 19:36 UTC

Amphastar Pharmaceuticals is declining today, continuing a downward trend since Thursday. The stock reached a session low earlier this morning amid broader market volatility.

30. juuli 2026, 19:28 UTC

Amphastar Pharmaceuticals Inc. shares are lower amid significant downward pressure in the Pharmaceuticals sub-sector, reflecting broader sector weakness during Thursday's session.

29. juuli 2026, 20:41 UTC

Amphastar Pharmaceuticals shares are lower in after-market trading, continuing a decline amid rising crude oil prices and geopolitical tensions in the Middle East.

28. juuli 2026, 20:02 UTC

Amphastar Pharmaceuticals shares are higher today, diverging from a broader market decline amid a sell-off in technology stocks across Asian markets.

24. juuli 2026, 19:06 UTC

Amphastar Pharmaceuticals is trading higher, supported by a pullback in crude oil prices, which has eased some inflationary pressures affecting investor sentiment.

22. juuli 2026, 20:06 UTC

Amphastar Pharmaceuticals Inc shares are lower today, continuing a four-session decline amid market uncertainty ahead of the Federal Reserve meeting on July 29.

21. juuli 2026, 19:46 UTC

Amphastar Pharmaceuticals Inc is trading lower, continuing a three-session decline. No specific news was identified to explain the stock's performance.

20. juuli 2026, 19:56 UTC

Amphastar Pharmaceuticals is gaining modestly during Monday's session amid mixed market conditions and geopolitical tensions affecting oil prices and inflation concerns.

Võrdlus sarnastega

Hinnamuutus

Amphastar Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

8.8% tõus

12 kuu keskmine prognoos

Keskmine 22 USD  8.8%

Kõrge 30 USD

Madal 19 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Amphastar Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

6 ratings

0

Osta

5

Hoia

1

Müü

Sentiment

By Acuity

19 / 340 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
help-icon Live chat